Skip to main content

October 2022 Drug Utilization Review Board Meeting Summary

Last updated on

The Texas Drug Utilization Review (DUR) Board met on Friday, October 21, 2022, to recommend Texas Medicaid clinical prior authorizations and drugs for the preferred drug list (PDL). A summary of this meeting is now available from the Texas Vendor Drug Program (VDP) website.

Clinical Prior Authorization Reminders

The following are reminders for clinical prior authorizations:

PDL Reminders

The following are reminders for the PDL:

  • All PDL recommendations are pending until the Texas Health and Human Services Commission (HHSC) executive commissioner releases the final decision. HHSC will incorporate the approved decisions from the July and October 2022 board meetings into the PDL published in January 2023.
  • Prescribing providers must use the Medicaid formulary and PDL.
  • MCOs adhere to the Medicaid formulary and PDL. Providers should evaluate a drug’s formulary status before its preferred status.

About the Texas DUR Board

The board’s next meeting will be on Friday, January 20, 2023. Board members meet quarterly in Austin to recommend outpatient prescription drugs in Texas Medicaid. The schedule of upcoming meetings, instructions on submitting written materials to the board, and directions about publicly testifying in front of the board are available on the Texas VDP website.

Contact vdp-advisory@hhsc.state.tx.us with comments or any questions.